Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benserazide in Beta Thalassemia Intermedia and Sickle Cell Disease
NCT04432623Phase 2Enrolling by invitation
- Sponsor
- Phoenicia Biosciences, Inc.
- Start
- Oct 2020
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of benserazide in beta-thalassemia intermedia and sickle cell disease (SCD) (5 arms), sponsored by Phoenicia Biosciences, Inc. Primary endpoints: Safety and Tolerability at 24 weeks, Maximum plasma concentration at 4 weeks and 1 more. Started Oct 2020; status: enrolling by invitation.
02
Drugs
benserazide
03
Conditions
beta-thalassemia intermediasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04432623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432623.